What is BioCardia, Inc.'s market cap?

BioCardia, Inc. (BCDA) has a market capitalization of $13.3M and trades on NASDAQ.

Who are BioCardia, Inc.'s competitors?

BioCardia, Inc.'s key competitors include LeMaitre Vascular, Inc., Creative Medical Technology Holdings, Inc. Common Stock, Capricor Therapeutics Inc, and others. These companies compete in similar markets and product categories.

Who does BioCardia, Inc. partner with?

BioCardia, Inc.'s notable partners include Biomet Biologics, LLC, CART-TECH.

What subsidiaries does BioCardia, Inc. have?

BioCardia, Inc.'s subsidiaries include BioCardia Lifesciences, Inc..

Where is BioCardia, Inc. headquartered?

BioCardia, Inc. is headquartered in United States of America and employs approximately 20 people. It has been publicly traded since 1995.

BioCardia, Inc.

BCDA

BioCardia is a clinical-stage biotechnology company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.

Market cap

$13.28M-0.5%

Table of contents

Earnings

Q1 2026 report

May 15, 2026

EPS-$0.21Miss by $0.04

Read the full report

Next report

Aug 10, 2026 (In 4 weeks)

EPS estimate-$0.19

Competitors

By market cap

LeMaitre Vascular$2.3B+24.8%

Capricor Therapeutics$1.3B+188%

Allogene Therapeutics$724.8M+186%

Cabaletta Bio, Inc.$507.9M+279%

Cartesian Therapeutics, Inc.$284.1M+1.6%

Caribou Biosciences, Inc.$192.4M+48.8%

BCD

BioCardia, Inc.$13.3M+22.2%

Creative Medical Technology Holdings, Inc.$6.1M-10.7%

By net margin

LeMaitre Vascular24.35%+4.4pp

Capricor Therapeutics-736.62%—

Allogene Therapeutics-1,170,863.64%—

Profile

BioCardia is a clinical-stage biotechnology company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company leverages proprietary autologous and allogeneic cell therapy platforms alongside specialized delivery systems to treat conditions like heart failure and chronic myocardial ischemia. Its core value proposition lies in providing minimally invasive, catheter-based regenerative treatments for significant unmet medical needs.

Competitive position

A clinical-stage innovator with FDA Breakthrough Device Designation for its lead cardiac cell therapy and a proprietary delivery platform used in multiple clinical trials.

GeographiesUnited States, Japan

Customer segmentsSpecialist Care Providers, Biopharmaceutical Partners, Healthcare Systems

Business modelR&D, Licensing, Direct Sales, Manufacturing

SuppliersThird-party component suppliers, Contract manufacturing organizations, Bone marrow donor networks

CustomersCardiology departments, Tertiary care hospitals, Biopharmaceutical development partners

CountryUnited States of America

Listed1995

Employees20.0

CEOPeter A. Altman

SectorHealthcare

IndustryBiotechnology

Websitebiocardia.com

FilingsSEC EDGAR

Questions, answered.

What is BioCardia, Inc.'s market cap?: BioCardia, Inc. (BCDA) has a market capitalization of $13.3M and trades on NASDAQ.
Who are BioCardia, Inc.'s competitors?: BioCardia, Inc.'s key competitors include LeMaitre Vascular, Inc., Creative Medical Technology Holdings, Inc. Common Stock, Capricor Therapeutics Inc, and others. These companies compete in similar markets and product categories.
Who does BioCardia, Inc. partner with?: BioCardia, Inc.'s notable partners include Biomet Biologics, LLC, CART-TECH.
What subsidiaries does BioCardia, Inc. have?: BioCardia, Inc.'s subsidiaries include BioCardia Lifesciences, Inc..
Where is BioCardia, Inc. headquartered?: BioCardia, Inc. is headquartered in United States of America and employs approximately 20 people. It has been publicly traded since 1995.